Literature DB >> 11169148

Expression of CD31, Met/hepatocyte growth factor receptor and bone morphogenetic protein in bone metastasis of osteosarcoma.

K Arihiro1, K Inai.   

Abstract

The mechanism of metastasis of osteosarcoma cells to other bones has not yet fully been clarified. The purpose of the present study was to examine whether various factors involve the formation of osteosarcoma metastatic foci in other bones. Immunohistochemically, CD31 expression in osteosarcoma with no bone metastasis and osteosarcoma with bone metastasis was noted in 10 and 75% of cases, respectively. Met/hepatocyte growth factor (HGF) receptor expression in osteosarcoma with no bone metastasis and osteosarcoma with bone metastasis was noted in 90 and 25% of cases, respectively. Bone morphogenetic protein (BMP) expression in osteosarcoma with no bone metastasis and osteosarcoma with bone metastasis was noted in 20 and 75% of cases, respectively. Metastasis of osteosarcoma cells to other bones was significantly correlated with expression of BMP and CD31 and with no expression of Met/HGF receptor protein in osteosarcoma cells. In contrast, expression of insulin-like growth factor receptor in osteosarcoma cells did not correlate significantly with bone metastasis. These results suggest that formation of metastatic foci of osteosarcoma cells in other bones is regulated by CD31, which is associated with migration between endothelial cells, by BMP, which can induce and activate various mesenchymal cells affecting bone formation, and by escape of effect by HGF, which promotes differentiation of osteosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11169148     DOI: 10.1046/j.1440-1827.2001.01164.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  5 in total

1.  Bone morphogenetic protein modulator BMPER is highly expressed in malignant tumors and controls invasive cell behavior.

Authors:  J Heinke; M Kerber; S Rahner; L Mnich; S Lassmann; T Helbing; M Werner; C Patterson; C Bode; M Moser
Journal:  Oncogene       Date:  2011-10-24       Impact factor: 9.867

2.  c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.

Authors:  E Gregory MacEwen; Jon Kutzke; Jennifer Carew; Josep Pastor; Julie A Schmidt; Rachel Tsan; Douglas H Thamm; Robert Radinsky
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

3.  Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K-AKT Signaling for the Treatment of Metastatic Osteosarcoma.

Authors:  Branden A Smeester; Garrett M Draper; Nicholas J Slipek; Alex T Larsson; Natalie Stratton; Emily J Pomeroy; Kelsie L Becklin; Kenta Yamamoto; Kyle B Williams; Kanut Laoharawee; Joseph J Peterson; Juan E Abrahante; Susan K Rathe; Lauren J Mills; Margaret R Crosby; Wendy A Hudson; Eric P Rahrmann; David A Largaespada; Branden S Moriarity
Journal:  Mol Cancer Ther       Date:  2020-09-30       Impact factor: 6.261

4.  Chip-based comparison of the osteogenesis of human bone marrow- and adipose tissue-derived mesenchymal stem cells under mechanical stimulation.

Authors:  Sang-Hyug Park; Woo Young Sim; Byoung-Hyun Min; Sang Sik Yang; Ali Khademhosseini; David L Kaplan
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

5.  Aberrant ADAM10 expression correlates with osteosarcoma progression.

Authors:  Ren Zhao; Dongjing Ni; Yi Tian; Bing Ni; Aimin Wang
Journal:  Eur J Med Res       Date:  2014-02-18       Impact factor: 2.175

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.